All In Biotech

Drug Trial Radar · NCT02398773

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

May 4, 2016

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
NIH
First posted
Mar 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may "light up" where cancer is in the body. Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment.

Conditions

  • HER2/Neu Negative
  • Progesterone Receptor Negative
  • Progesterone Receptor Positive
  • Stage IV Breast Cancer AJCC v6 and v7

Interventions

  • Computed TomographyProcedure

    Undergo PET/CT

  • F-18 16 Alpha-FluoroestradiolDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Positron Emission TomographyProcedure

    Undergo PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Negative predictive value of 18F FES uptake for response (CB), defined as the proportion of patients with a negative FES test result who have progressive diseaseTime frame: At 6 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Sidney and Lois Eskenazi Hospital

    Indianapolis, Indiana

  • Springmill Medical Center

    Indianapolis, Indiana

  • Mayo Clinic in Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Mount Sinai Hospital

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Fox Chase Cancer Center - East Norriton Hospital Outpatient Center

    East Norriton, Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah

  • University of Washington Medical Center - Montlake

    Seattle, Washington

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin

  • ProHealth D N Greenwald Center

    Mukwonago, Wisconsin

  • ProHealth Oconomowoc Memorial Hospital

    Oconomowoc, Wisconsin

  • ProHealth Waukesha Memorial Hospital

    Waukesha, Wisconsin

  • UW Cancer Center at ProHealth Care

    Waukesha, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.